Study finds cancer trial drug may prevent Alzheimer’s disease

A study using mice has uncovered a possible new cause of Alzheimer’s disease, and suggests a drug currently being investigated in human clinical trials to treat cancer could prevent the illness.

The research has been heralded as offering hope of finding new treatments for dementia.

The findings, by Duke University in America and published in the Journal of Neuroscience, are surprising, according to one of the authors, as they contradict current thinking on the disease.

The research suggests that with Alzheimer’s disease certain immune cells that normally protect the brain begin abnormally to consume an important nutrient called arginine.

By blocking this process using the drug difluoromethylornithine (DFMO), memory loss and a build-up of sticky proteins known as brain plaques, were prevented.

The study used a type of mouse in which a number of important genes have been swapped to make the animal’s immune system more similar to a human’s.

Immune system

Senior author Carol Colton, professor of neurology at the Duke University School of Medicine, and a member of the Duke Institute for Brain Sciences, said: “If indeed arginine consumption is so important to the disease process, maybe we could block it and reverse the disease.”

It was previously thought the brain releases molecules which ramp up the immune system, apparently damaging the brain, but the study found a heightened expression of genes associated with the suppression of the immune system.

Author Matthew Kan said: “It’s surprising, because (suppression of the immune system is) not what the field has been thinking is happening in AD (Alzheimer’s disease).”

Mice which had been given the drug DFMO to block arginase, an enzyme that breaks down arginine, were found to perform better in memory tests.

“All of this suggests to us that if you can block this local process of amino acid deprivation, then you can protect – the mouse, at least – from Alzheimer’s disease,” Mr Kan said.